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Significance 
Breakdown of the blood–retinal barrier (BRB) is central to diabetic macular edema (DME). Here, we 
demonstrate that lipoprotein-associated phospholipase A2 (Lp-PLA2) plays a critical role in diabetes-related 
retinal vasopermeability, a response that is mediated by lysophosphatidylcholine (LPC). Because neutralization 
of VEGF is the current gold-standard treatment for DME, we assessed suboptimal systemic treatment of an Lp-
PLA2 inhibitor alongside a suboptimal intravitreal injection with a rat-specific VEGF antibody and demonstrated 
that protection against diabetes-mediated retinal vasopermeability was additive. We have also shown a 
coalescence of the LPC and VEGF pathways in retinal vascular endothelium via a common VEGF receptor 2-
mediated mechanism. Alongside currently administered anti-VEGF agents, Lp-PLA2 may be a useful therapeutic 
target for DME.  
  
Abstract 
Lipoprotein-associated phospholipase A2 (Lp-PLA2) hydrolyses oxidized low-density lipoproteins into 
proinflammatory products, which can have detrimental effects on vascular function. As a specific inhibitor of 
Lp-PLA2, darapladib has been shown to be protective against atherogenesis and vascular leakage in diabetic 
and hypercholesterolemic animal models. This study has investigated whether Lp-PLA2 and its major enzymatic 
product, lysophosphatidylcholine (LPC), are involved in blood–retinal barrier (BRB) damage during diabetic 
retinopathy. We assessed BRB protection in diabetic rats through use of species-specific analogs of darapladib. 
Systemic Lp-PLA2 inhibition using SB-435495 at 10 mg/kg (i.p.) effectively suppressed BRB breakdown in 
streptozotocin-diabetic Brown Norway rats. This inhibitory effect was comparable to intravitreal VEGF 
neutralization, and the protection against BRB dysfunction was additive when both targets were inhibited 
simultaneously. Mechanistic studies in primary brain and retinal microvascular endothelial cells, as well as 
occluded rat pial microvessels, showed that luminal but not abluminal LPC potently induced permeability, and 
that this required signaling by the VEGF receptor 2 (VEGFR2). Taken together, this study demonstrates that Lp-
PLA2 inhibition can effectively prevent diabetes-mediated BRB dysfunction and that LPC impacts on the retinal 
vascular endothelium to induce vasopermeability via VEGFR2. Thus, Lp-PLA2 may be a useful therapeutic target 
for patients with diabetic macular edema (DME), perhaps in combination with currently administered anti-
VEGF agents.  
diabetic retinopathy ,VEGF signaling, lysophosphatidylcholine, blood–retinal barrier, lipoprotein-associated 
phospholipase A2 
  
Breakdown of the blood–retinal barrier (BRB) is a significant pathophysiological event during diabetic 
retinopathy (DR). Leakage of plasma proteins and lipids into the neuropile form exudates, whereas excessive 
vasopermeability can lead to diabetic macular edema (DME), which is a major cause of vision loss (1). Both 
DME in patients and BRB dysfunction in animal models have been linked to inflammatory processes, 
endothelial dysfunction, and compromise of normal neuroglial–vascular interactions (2). A number of 
therapeutic options are available to treat DME. Laser photocoagulation is effective in slowing the progression 
of DME; however, it carries risk of serious adverse side effects including visual field defects, retinal scarring, 
and foveal burns. Intravitreal injection of antiinflammatory corticosteroids has proven value, but this 
intervention also carries significant side effects including cataract formation and elevated intraocular pressure. 
More recently, neutralization of vascular endothelial growth factor (VEGF) in the retina has become a 
mainstream treatment of DME (3) although this is not effective for all DME patients (4). Moreover, repeated 
intravitreal injections can result in some patients becoming refractory to VEGF blockade (5), which suggests 
that other mechanisms also drive vascular permeability during DME. Concerns have also been raised that 
targeting the VEGF pathway could inadvertently compromise retinal neuroglial and microvascular survival (6) 
although, thus far, no evidence of these outcomes have been observed in clinical trials of anti-VEGF for DME. 
Nevertheless there is a need for additional therapeutic approaches to treat DME, either alone or adjunctively 
with currently available therapeutics.  
An alternative permeability-inducing agent in diabetic retina could be lysophosphatidylcholine (LPC), which is 
elevated in plasma of diabetic patients (7) and has demonstrated permeability-enhancing activity in cultured 
nonneural endothelial cells (ECs) (8). The principal enzyme responsible for the production of LPC is a calcium-
independent phospholipase A2 called lipoprotein-associated phospholipase A2 (Lp-PLA2) (also known as 
platelet-activating factor acetylhydrolase or type VIIA PLA2). Lp-PLA2 can elicit a broad range of 
proinflammatory and proapoptotic effects in blood vessels related to its hydrolysis of modified 
polyunsaturated fatty acids within oxidized low-density lipoprotein (oxLDL) into LPC and oxidized nonesterified 
fatty acids (OxNEFA) (9). Elevated Lp-PLA2 has been proposed as a predictive biomarker in stroke (10), 
atherosclerosis (11), and coronary heart disease (12). Macrophages and other proinflammatory cells are a 
primary source of Lp-PLA2 in the systemic circulation (13), although endothelial cells also express this enzyme 
(14).  
Darapladib, a specific inhibitor of Lp-PLA2, has been shown to reduce atherosclerosis in both 
diabetic/hypercholesterolemic pigs (15) and ApoE-deficient mice (16). In diabetic/hypercholesterolemic pigs, 
darapladib protected against blood–brain barrier (BBB) dysfunction and vascular permeability (17). Darapladib 
has been studied in nearly 16,000 patients with coronary heart disease, and approximately one-third of this 
study population had diabetes mellitus (18). In a further study, a 3-month daily treatment with 160 mg of 
darapladib orally showed reduction of DME and an improvement in visual acuity in patients (19). These 
observations suggest that Lp-PLA2 and its mechanism of action warrant further investigation in the context of 
DR. In this study, we have studied the inhibition of Lp-PLA2 in diabetic rats with regards to BRB function and 
assessed the effect of LPC on neural microvascular endothelial cells. We show inhibition of Lp-PLA2 was 
effective in reducing diabetes-induced retinal vasopermeability and that the effect of this inhibition was 
additive with VEGF neutralization, suggesting this enzyme could be an efficacious therapeutic target for DME, 
either alone or in combination with anti-VEGF therapeutics.  
Results 
Enhanced Lp-PLA2 Activity During Diabetes Can Be Inhibited by Using SB435495.  
Diabetes induction in Brown Norway (BN) rats resulted in significant hyperglycemia and weight loss, whereas 
treatment with SB435495, a rodent-specific analog of darapladib, had no effect on these parameters (Fig. S1 A 
and B). SB435495 inhibited Lp-PLA2 in BN rat plasma with an IC50 of 8.8 ± 1.3 nM (Fig. 1A). Dosing of diabetic 
BN rats at 0.25, 1, 5, and 10 mg/kg SB435495 for 28 d reduced plasma Lp-PLA2 activity levels to 72.8%, 57.5%, 
33.5%, and 19.1%, respectively, compared with Lp-PLA2 activity measured in plasma collected from rats before 
treatment (P < 0.0001) (Fig. 1B). This inhibition corresponded to SB435495 levels that accumulated in the 
plasma (P < 0.001) (Fig. 1C). Lp-PLA2 activity was also measured in nondiabetic control and diabetic BN rat 
plasma collected at day 0 (before placebo administration) and day 28 of diabetes (after daily placebo 
administration). Lp-PLA2 activity was elevated by approximately threefold in the plasma of diabetic rats 
compared with that of nondiabetic controls (P < 0.0001) (Fig. 1D). Enhanced Lp-PLA2 activity in diabetic BN rats 
was sustained for the 28-d duration of the experiment.  
Lp-PLA2 Inhibition Limits Diabetes-Induced Retinal Vasopermeability.  
BRB integrity was quantified by measuring Evans blue extravasation in the retinae of BN rats that had been 
diabetic for 4 wk. Diabetes led to a significant retinal vasopermeability in BN rats compared with nondiabetic 
controls [nondiabetic control (NDB CON) mean = 2.291 vs. diabetic (DB) + placebo mean = 4.160 µL⋅g
−1
⋅h
−1
] 
(Fig. 2A), and this result is comparable to what has been shown in other studies using BN rats for this diabetes-
duration time frame (20). SB435495 treatment at 10 mg/kg significantly attenuated diabetes-induced retinal 
vasopermeability (P < 0.002) (Fig. 2A).  
As an additional approach to the Evans blue method, we analyzed histological aspects of diabetes-induced 
vasopermeability in BN rats using retinal sections from each treatment group stained for albumin 
extravasation from isolectin B4-stained retinal blood vessels. Quantification of albumin immunoreactivity 
revealed a significant increase in diabetic retina and a nearly complete reversal to control levels following 
treatment with 10 mg/kg SB435495 (P < 0.0001) (Fig. 2B). In control animals, albumin staining was confined to 
lectin-positive vessel structures (Fig. 2 C, i), whereas sections from diabetic animals displayed many areas of 
extravascular albumin staining throughout the retinal neuropile, indicative of enhanced vascular leakage (Fig. 2 
C, ii and Figs. S2 and S3). This albumin leakage was focal in nature and mostly occurred in the vicinity of vessels 
that appeared strongly dilated. Treatment with SB435495 (10 mg/kg) resulted in a strong reduction of these 
areas of albumin leakage, to levels similar to that observed in the nondiabetic control rat retina (Fig. 2 C, iii vs. 
Fig. 2 C, i). This morphological approach in an additional group of animals using an independent 
vasopermeability detection method corroborates our Evans Blue data.  
We also tested the effect of SB435495 on diabetes-induced vasopermeability in a therapeutic setting. For this 
experiment, BN rats that had been diabetic for 28 d were treated with placebo or SB435495 by a daily 10 
mg/kg i.p. injection for an additional 28 d. Retinal vasopermeability was assessed by analysis of albumin 
immunoreactivity in retinal sections. Compared with the nondiabetic controls, vehicle-treated diabetic animals 
displayed clear extravasation of albumin (Fig. S3). In contrast, the SB435495-treated animals demonstrated a 
clear effect in limiting extravasation of albumin at the end of the treatment period, indicating that both 
preventive and therapeutic Lp-PLA2 inhibition by SB435495 effectively reduced retinal vascular leakage in 
diabetic BN rats.  
Synergistic Effect of VEGF and Lp-PLA2 Neutralization on BRB Function.  
We next investigated how Lp-PLA2 inhibition interacted with blockade of the VEGF signaling axis. Diabetic BN 
rats were treated with either control IgG antibodies, or the anti-rat VEGF neutralizing antibody DMS1529, 
either alone or in combination with SB435495 treatment. Control IgG antibody and VEGF neutralizing 
antibodies were administered as 1-µL intravitreal injections in both eyes at day 26 of diabetes. SB435495 was 
administered i.p. for 28 d and retinal vasopermeability assessed by Evans blue assay. Retinal vasopermeability 
was significantly elevated in diabetic/IgG-treated rats compared with nondiabetic controls (P < 0.05) (Fig. 3). 
Intravitreal injection of diabetic rats with anti-VEGF antibody (0.5 mg/mL) had no statistically significant effect 
on vasopermeability, nor did SB435495 at a dose of 5 mg/kg in combination with IgG (Fig. 3B). In contrast, 
higher concentrations of anti-VEGF antibody (1 mg/mL) or SB435495 (10 mg/kg) were highly effective in 
suppressing diabetes-induced vasopermeability. When suboptimal intravitreal anti-VEGF injection (0.5 mg/mL) 
was combined with suboptimal regimen of SB435495 (5 mg/kg), there was a significant reduction in retinal 
vasopermeability compared with suboptimal monotherapy (P < 0.05).  
LPC-Induced Vasopermeability in Neural Microvascular Endothelium. 
Lp-PLA2 enzymatic activity produces LPC, which induces vasopermeability in cultured dermal and lung 
microvascular endothelial cells (MVECs) (8). To understand the action of diabetes-induced Lp-PLA2 activity, we 
investigated the effect of LPC on brain and retinal endothelium. MVECs with highly preserved interendothelial 
junctions, apico-basal polarity, and barrier properties (21) were isolated from rat brain or retinae. Brain MVECs 
were readily isolatable and used at passage 0, whereas retinal MVECs were further subcultured by one round 
of trypsinization. Treatment of brain MVECs with LPC caused a significantly enhanced flux of 4-kDa FITC-
dextran in a dose-dependent manner (P < 0.05–0.001) (Fig. 4A) and transiently reduced transendothelial 
electrical resistance (TEER) (P < 0.0001) (Fig. 4B), indicating that paracellular permeability was induced. 
Maximal disruption of the barrier was evident after less than 10 min of LPC addition. In retinal MVECs (Fig. 4C), 
LPC also induced a transient drop in TEER, albeit of less potency and at slightly later time (approximately 15 
min) (P < 0.05) compared with the brain MVECs, which possibly reflected the effect of passaging of the retinal 
MVECs (21).  
LPC also induced vasopermeability in occluded rat pial microvessels in vivo. Significantly, it was only effective 
when administered from the luminal (blood) but not the abluminal (tissue) side (P < 0.05) (Fig. 4 D–G). 
Similarly cultured brain MVECs responded with enhanced flux in response to apically but not basally applied 
LPC (Fig. 4 H), indicating that directionality was brought about by the endothelium itself.  
In the retina and the brain, VEGF-A induces endothelial permeability via activation of p38 (21); therefore, the 
relationship between LPC and this VEGF-induced signaling pathway in MVECs was assessed. LPC treatment of 
the retinal MVEC line PT2 (described in Figs. S4 and S5) led to enhanced phosphorylation of p38 within 5 min 
(P < 0.005) (Fig. 5A). LPC also led to phosphorylation of the VEGFR2 on Y1175, which was comparable to that 
induced by VEGF-A itself (P < 0.01) (Fig. 5B). This phosphorylation was suppressed by preincubation with the 
VEGFR2-specific kinase antagonist SU1498, indicating potential transactivation. SU1498 also inhibited LPC-
induced reduction of TEER in brain and retinal MVECs (P < 0.01) as did another VEGFR2 kinase antagonist, 
PTK/ZK, with different overall specificity (P < 0.001) (Fig. 5 C and D). SU1498 also inhibited LPC-induced flux in 
brain MVECs in vitro (P < 0.01) (Fig. 5E). However, neutralization of VEGF-A using either the antibody DMS1529 
or aflibercept (EYELEA) failed to affect LPC-induced flux across brain MVECs (Fig. 5 E and F), indicating that 
VEGF secretion was not responsible for VEGFR2 transactivation. To confirm the definitive involvement of 
VEGFR2 in LPC-induced permeability, electrical barrier breakdown was measured in primary brain MVECs 
infected with shRNA-coding adenovirus 48 h before LPC addition (Fig. 5G). Infection with a virus targeting 
VEGFR1 had no effect on LPC-induced TEER reduction. Significantly, infection with a virus that led to 
knockdown of VEGFR2, attenuated LPC-induced barrier breakdown (P < 0.01), indicating that LPC requires 
VEGFR2 kinase activity to induce vasopermeability. The requirement of VEGFR2 for LPC-induced permeability 
was also corroborated in pial microvessels in vivo, where SU1498 completely suppressed the permeability 
response to LPC (Fig. 5H).  
Discussion 
Lp-PLA2 has been proposed as a circulating biomarker for inflammatory disease, whereas increased activity of 
Lp-PLA2 has been linked to vascular dysfunction (22). The pathogenic role of Lp-PLA2 has been mostly focused 
on the macrovasculature and atherosclerosis, but the current study indicates that Lp-PLA2 could also play an 
important role in retinal microvascular pathology during diabetes. During diabetes oxLDL is specifically found 
at sites of retinal vascular and glial cell damage (23) and this association could be mediated, at least in part, by 
abnormal Lp-PLA2 activity in the blood stream or even by the retinal vasculature itself. Lp-PLA2-associated 
damage to the vasculature is mediated by its bioactive reaction products, LPC and OxNEFA, which promote 
prooxidant and proinflammatory activity on the endothelium (24) and induce vasopermeability (8). LPC levels 
in plasma and Lp-PLA2 activity have been reported to be elevated in diabetic patients (7). The current study has 
also demonstrated a significant increase in Lp-PLA2 activity in serum from diabetic rats.  
DME in patients usually takes years to manifest, although comparatively short-term diabetes in rodents has 
been used as a model system to study retinal vasopermeability and BRB compromise as retinopathy 
progresses (25). For the current study, the BN rat model was chosen because this strain demonstrates a robust 
and sustained breakdown of the BRB when rendered diabetic, a response that is clear after 4 wk and beyond 
(20). Evan’s blue extraction allowed quantitative measure of BRB damage in this model, whereas 
immunohistochemistry demonstrated the focal nature of vasopermeability in the diabetic BN rats, which is 
related to endothelial dysfunction. Darapladib is a selective inhibitor of Lp-PLA2 with demonstrable efficacy 
against atherogenesis in preclinical models (15). In diabetic and hypercholesterolemic pigs, darapladib 
prevents leakage of circulating IgG into the brain parenchyma, suggesting a protective effect of BBB function 
(17) while some pyrimidone derivatives have been shown to inhibit Lp-PLA2 activity and reduce morphological 
changes to retinal layers in diabetic rats (26). However, the consequence or mechanism of Lp-PLA2 inhibition 
on retinal vascular permeability has not yet been investigated. The data presented herein show amelioration 
of a similar BRB dysfunction in diabetic rats by using the darapladib analog SB435495 and supports the 
modulatory role of Lp-PLA2 in retinal vasopermeability. Additional data generated in Lp-PLA2-suppressed 
rabbits indicated that the lipase did not affect the vasopermeability pathway directly, at least not that induced 
by VEGF (Fig. S4 and Table S1). Thus, it is likely that Lp-PLA2 affected retinal vasopermeability in diabetes 
through its plasma oxLDL reaction product, LPC.  
We confirmed the permeability-inducing effect of LPC in microvascular endothelium of neural origin in vitro 
and in vivo. Brain and retinal microvascular endothelial cells showed significant dose-dependent permeability 
responses to LPC, and this response was also true in an in vivo model of occluded pial microvessels. The 
precise nature of the endothelial LPC receptor is unknown, but this lipid has been reported to act as a 
multiactivity ligand, binding a number of proteins including: the CD36 scavenger receptor, Toll-like receptors 
(TLR4 and TLR2), and also the lectin-like oxLDL receptor-1 (LOX-1), after which it triggers a range of prooxidant 
and proinflammatory pathways (27⇓–29). Studies also implicate G protein-coupled receptors in mediating LPC 
function (30). Interestingly, LPC only exerted this action from the luminal vessel side or the apical side of the 
endothelium, and indicated that elevated plasma LPC in diabetes can act on the luminal side of the 
endothelium to induce vascular leakage. Interestingly, this effect is opposite to what is observed for VEGF-A 
(21). In agreement to others (31), we also found that LPC transactivated VEGFR2, and that this transactivation, 
which did not require VEGF, was a key signaling pathway in the induction of LPC-induced permeability both in 
vitro and in vivo. Transactivation of VEGFR2 may thus occur within the cell, possibly through reactive oxygen 
species (32). Taken together, our data lend further support to the central role of VEGFR2 and its kinase activity 
in VEGF-dependent and independent vascular permeability.  
The role of VEGF in vasopermeability is well-established, and delivery of this growth factor into mammalian 
eyes can induce a transient but robust breakdown of the BRB (25), which may be mediated by alteration of 
paracellular tight-junction integrity (33) and induction of a transcellular vesicular pathway (34). The 
importance of VEGF in DME has found ultimate credence by the observation that many patients’ retinal edema 
and vision impairment improves significantly in response to regular intravitreal injections of anti-VEGFs, such 
as ranibizumab (35). However, at least 50% of patients do not clinically respond, or respond in a delayed 
manner, to VEGF neutralization, suggesting alternative permeability factors may be involved (2). Here, we 
propose Lp-PLA2 activity and its plasma-borne reaction products may constitute another pathway to retinal 
vasopermeability. Indeed, a parallel prospective phase IIa study shows that darapladib, given over a 3-month 
period, leads to improvement in DME-associated vision loss and edema (19).  
In diabetic BN rats, suboptimal SB435495 application combined with suboptimal VEGF neutralization (using 
DMS1529) led to effective suppression of retinal vasopermeability, suggesting that two partially independent 
but additive pathways were targeted. Importantly, our rabbit data showed that Lp-PLA2 inhibition did not 
affect the VEGF-induced vasopermeability pathway, also underlining that these pathways are somewhat 
distinct. We also found that there was a coalescence of these two pathways because LPC-induced 
microvascular permeability in vitro and in vivo depended on VEGFR2 signaling. Further studies are needed to 
clarify the effect of Lp-PLA2 products on the BRB microvasculature as well as LPC-induced endothelial signaling 
and its crosstalk with other permeability pathways. Importantly, data from the present study has identified Lp-
PLA2 as a valid VEGF-independent therapeutic target in DME, but also indicated that Lp-PLA2 inhibition could 
be combined with that of VEGF. This finding opens the possibility of combination therapy with the benefits of 
use of lower drug dosages and lower potential toxicity.  
Materials and Methods 
Lp-PLA2 Inhibition in Diabetic Rats and Prevention of Diabetes-Induced Retinal Vasopermeability.  
All experiments using animals conformed to U.K. Home Office regulations. Furthermore, studies were carried 
out in accordance with the European Directive 86/609/EEC, the GlaxoSmithKline Policy on the Care, Welfare, 
and Treatment of Animals, and the Association for Research in Vision and Ophthalmology (ARVO) Statement 
on the Use of Animals in Ophthalmic and Vision Research. Diabetes was induced in male adult BN rats (20). For 
detailed protocols and assessment of diabetes status, refer to SI Materials and Methods. SB-435495 and SB-
568859 (GlaxoSmithKline) are potent and selective pharmacological inhibitors of Lp-PLA2 in a variety of species 
(36, 37). Pharmacokinetic properties of SB-568859 were most applicable to studies in rabbits, whereas SB-
435495 was best suited for studies in rats (38). Details of formulation, plasma drug levels, and enzymatic 
activity is available in SI Materials and Methods.  
Diabetic rats were randomly assigned into groups receiving either a once-daily i.p. injection of placebo 
(vehicle) or once-daily dosing of SB435495 (dose range: 0.25–10 mg/kg). A control group of nondiabetic, age-
matched rats received no treatment. After 28 d, animals were processed for analysis of retinal 
vasopermeability. In further studies where the effect of combination of anti-VEGF and SB435495 therapies on 
diabetes-induced retinal vasopermeability was studied, anti-VEGF or control antibodies were introduced by 
intravitreal injections in both eyes, at day 26 after initial SB435495 administration. Retinal vasopermeability 
indicating breakdown of the BRB was assessed by using the Evans blue assay as described (25). Additionally, 
albumin leakage into the retina was analyzed by using immunohistochemistry.  
Vascular Permeability in MVECs and Pial Microvessels. 
Primary MVECs were isolated from rat brains or retinae and grown as described (21). A stable rat retinal MVEC 
line (PT2) was also used to provide the larger cell quantities necessary for biochemical analyses (Fig. S5) (39). 
For some experiments, cells were infected with recombinant adenoviruses carrying small hairpin RNAs 
targeting either mouse or rat VEGFR1 or VEGFR2. LPC was diluted into PBS, which was supplemented with 
0.1% fatty-acid free BSA and flux measurements performed as described by using 4-kDa FITC-dextran (21). For 
TEER assays, cells were grown on 12-mm gold-coated ECIS grids (8W1E), and real-time impedance was 
acquired by using a 1600R device and firm software to derive TEERs. Detailed methods are available in SI 
Materials and Methods and Table S1.  
In vivo permeability measurements in occluded pial microvessels were performed on rats as described by 
Hudson et al. (21), and details are provided in SI Materials and Methods.  
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Fig. 1. Lp-PLA2 inhibition and SB435495 plasma concentration in BN rat plasma. (A) Lp-PLA2 activity was 
measured in the presence of increasing concentrations of SB435495. The IC50 was calculated as 8.8 ± 1.3 nM. 
(B) Activity of Lp-PLA2 was measured following SB435495 administration for 28 d in diabetic rats. Mean ± SEM 
are shown, n = 8 per treatment group (***P = 0.0001, one-way ANOVA analysis). (C) Mean systemic SB435495 
concentrations in terminal plasma samples from BN rats. SB435495 concentrations were detected by 
HPLC/MS/MS expressed in ng/mL (***P < 0.0001, one-way ANOVA analysis) (n = 12 for 10, 5, and 1 mg/kg 
groups, n = 11 for 0.25 mg/kg SB435495 group). (D) Lp-PLA2 activity in diabetic (DB) and nondiabetic (NDB) rat 
plasma collected at day 0 and day 28 of diabetes. Diabetes significantly increased Lp-PLA2 activity (P < 0.0001), 
which was sustained throughout the duration of the experiment. n = 13 NDB CON, n = 10 DB (day 0), n = 12 DB 
(day 28).  
  
 
Fig. 2. Suppression of diabetes-induced retinal vasopermeability by SB435495. (A) Quantification of Evans blue 
leakage into the retina was measured in nondiabetic (NDB) control, diabetic controls (DB CON), or SB435495-
treated diabetic rats. Retinal vasopermeability was significantly increased in DB CON compared with NDB (**P 
= 0.047, P < 0.05, t test). Lp-PLA2 inhibition with 10 mg/kg SB435495 reduced BRB breakdown (***P = 0.002, t 
test). Mean ± SEM, n = at least 8 animals per group. (B) Mean area of albumin-positive immunostaining in 
square micrometers measured in retinal sections dual stained with isolectin B4 and anti-rat albumin antibody. 
There was a statistically significant increase in albumin immunoreactivity in the DB CON sections, compared 
with NDB sections (***P < 0.0001, Mann–Whitney test). SB435495 (10 mg/kg) treatment reduced albumin 
immunoreactivity to that observed in the NDB retinal sections (***P < 0.0001, Mann–Whitney test). Means ± 
SEM n = 3 animals per group, 16 images per treatment analyzed. (C) Representative images of albumin/isolecin 
B4-stained retinal sections from NDB, DB CON, and SB435495-treated rats. Red channel, isolectin B4; green 
channel, anti-rat albumin; blue channel, DAPI. Significant vascular leak was observed in the diabetic + placebo-
treated animals (ii) compared with nondiabetic controls (i). Albumin leakage was reduced in the 10 mg/kg 
SB435495 group (iii). (Objective magnification: 40×.) n = 3 animals per treatment group. (Scale bars: 50 µm.)  
 
  
 
Fig. 3. Inhibition of retinal vasopermeability by Lp-PLA2. Effect of combined SB435495 and intravitreal 
DMS1529 (anti-VEGF domain antibody) on retinal vasopermeability in diabetic (DB) rats. SB435495 was given 
i.p. daily at the indicated doses. VEGF antibody (DMS1529) or isotype-matched IgG were bilaterally injected 
intravitreally at day 26. Retinal vasopermeability was significantly elevated in DB + IgG-treated rats, compared 
with NDB controls (one-way ANOVA, Bonferroni post test ***P < 0.05) (Fig. 3). Treatment with 1.0 mg/mL anti-
VEGF antibody or 10 mg/kg SB435495 +IgG treatment resulted in a significant reduction in retinal leakage 
compared with DB + IgG-treated rats (one-way ANOVA, Bonferroni post hoc test ***P < 0.05). Treatment with 
0.5 mg/mL anti-VEGF antibody alone or suboptimal 5 mg/kg SB435495 + IgG treatment had no effect on retinal 
vasopermeability. However, 0.5 mg/mL anti-VEGF antibody + 5 mg/kg SB435495 (suboptimal dose) treatment 
induced a significant reduction in retinal vasopermeability, compared with DB animals treated with 5 mg/kg 
SB435495 + IgG (one-way ANOVA, Bonferroni post hoc test **P < 0.05). Mean ± SEM, n = at least 14 animals 
per treatment group. 10 and 5, 10 and 5 mg/kg SB435495; 1.0 and 0.5, 1.0 and 0.5 mg/mL DMS1529 or IgG.  
  
 
Fig. 4. Effects of increased concentration of LPC on neural MVEC barriers. (A) Four-kilodalton dextran flux was 
measured in primary brain MVECs before and after the addition of the indicated concentrations of LPC. Shown 
are means ± SEM (n = 8 for vehicle, n = 4 for 1 µg/mL LPC, n = 5 for 3 µg/mL LPC, n = 10 for 10 µg/mL LPC) of 
averaged 2-h flux [one-way ANOVA (P = 0.022) Bonferroni post hoc tests: *P < 0.05, **P < 0.01]. (B and C) 
Primary rat brain (B) and retinal (C) EC were grown to confluence and until they reached full electrical barrier 
(TEER of approximately 25,000 Ω and 15,000 Ω, respectively). LPC was added at the indicated concentrations 
at time 0. Shown are means (± SEM) of normalized resistance changes. There were differences for both brain 
and retinal MVECs (brain MVECs: P < 0.0001) (retinal MVECs: P < 0.004) with Bonferroni post hoc analysis, 
indicating significant differences between vehicle and 10 μg/mL LPC (brain: P < 0.0001; retina: P < 0.05). (D) 
LPC induces microvascular permeability in pial vessels in vivo. Time-dependent recording of sulforhodamine B 
(580 Da) loss from single occluded rat pial microvessels in vivo. Luminal injection (via intracarotid) of 30 μg/mL 
LPC (assumed diluted to 10–15 μg/mL final in the brain) produced a strong decrease of sulforhodamine B after 
approximately 40 s. Abluminal application of LPC (10 μg/mL) through a cranial window at t = 20 s did not lead 
to any changes in permeability. Micrographs of pseudocolored microvessels at indicated times (minutes). 
Mean densitometric fluorescent intensities in microvessels plotted against time (E and F). Data were fitted 
(black and green trend lines) to the equation Ct = C0⋅e
-kt
. Black and orange data points represent times without 
and with LPC, respectively. (G) Mean permeability changes acquired as shown in D following abluminal (10 
μg/mL; n = 4) and luminal LPC (assumed 10–15 μg/mL final; n = 8) ± SEM P < 0.05 (Student’s t test). (H) Primary 
brain MVECs were grown on Transwell filters, and the flux of 4-kDa dextran was measured in response to 
apically or basally added LPC (10 µg/mL). Shown are means ± SEM (P < 0.01, Student’s t test).  
  
 
Fig. 5. Leakage induction of LPC via VEGFR2 signaling pathway. (A) Rat retinal MVECs (PT2) treated with LPC (10 
μg/mL), and levels of phosphorylated p38 (pT180/Y182) were determined by Western blotting. Shown is a 
representative blot and normalized densitometric quantifications (means ± SEM, n = 3, **P < 0.01, Student’s t 
test). (B) As in A, except that PT2 were pretreated with SU1498 (10 μM) for 1 h where indicated and then with 
LPC (10 μg/mL) or VEGF-A (50 ng/mL) for 5 min, and samples were immunoblotted for both phosphorylated 
(Y1175) and total VEGFR2. Shown are means ± SEM (n = 3) from one-way ANOVA analysis (P < 0.0001) 
(Dunnett’s post hoc test showed significant differences for LPC and VEGF (P < 0.01 and P < 0.0001, 
respectively). (C) Primary rat brain EC were grown to confluence and until they reached full electrical barrier. 
At times, 1-h cells were pretreated or not with SU1498 or PTK/ZK (both at 10 μM). LPC was added at time 0. 
Shown are means of normalized resistance changes. (D) Primary rat MVECs were grown to confluence and 
until they reached full electrical barrier and treated/analyzed as in C. One-way ANOVA (P < 0.01), Bonferroni 
post hoc test show significant differences between vehicle vs. LPC (P < 0.01) and LPC vs. LPC+PTK (P < 0.01) and 
LPC vs. LPC+SU (P < 0.05) (E) Postconfluent primary MVECs were pretreated in the presence or absence of 
SU1498 (10 µM) or DMS1529 (10 µg/mL) and 4-kDa dextran flux was measured before and after the addition 
of 10 µg/mL LPC. Means ± SEM (vehicle, n = 8; LPC, n = 8; SU+LPC, n = 8; DMS+LPC, n = 4) for one-way ANOVA 
and Dunnett’s post hoc test: *P < 0.05. (F) Flux experiment as described in E except that aflibercept (EYLEA; 25 
µg/mL) was added or not before measuring the flux induced by VEGF-A (50 ng/mL) or LPC (10 µg/mL). 
Significant increases in flux induced by VEGF-A were reversed by Aflibercept (***P < 0.01; Student’s t test). 
However, aflibercept did not reverse flux increases induced by LPC (not significant, Student’s t test). (G) 
Primary rat brain MVEC were grown until confluence and until they reached full electrical barrier and infected 
with shRNA-encoding adenovirus at a multiplicity of infection (m.o.i.) of 400, targeting either VEGFR1 
(shVR1.2) or VEGFR2 (shVR2.1). Forty-eight hours after infection, LPC (10 µg/mL) was added (time 0). 
Corresponding protein knockdown is shown in Inset. One-way ANOVA (P < 0.0001), Bonferroni post hoc 
analysis showed significant differences between BSA vs. LPC (P < 0.001) and LPC vs. VR2.1+LPC (P < 0.01) but 
not LPC vs. VR1.2+LPC (n = 4). (H) Permeability in pial rat microvessels in vivo following 20 μM SU1498 
pretreatment for 15 min before sulforhodamine loss in response to luminal LPC (10–15 μg/mL final) from 
occluded pial microvessels. Shown are mean (± SEM). *P < 0.05 (Student’s t test).  
  
SI Materials and Methods 
Lp-PLA2 Inhibition in Diabetic Rats.  
Diabetes was induced in male adult BN rats (150–190 g) by a single i.p. injection of streptozotocin (STZ; Sigma 
Aldrich) (60–65 mg/kg in 0.1 mol/L citrate buffer, pH 4.6). Diabetes in these animals is accompanied by 
sustained compromise of the BRB (20). At 10 d after STZ injection, glucometric analysis of tail prick blood 
samples (Breeze2; Bayer) was used to select diabetic animals (hyperglycemic with blood glucose concentration 
>15 mmol/L) for the remainder of the study. HbA1c (glycated hemoglobin) levels were measured in terminal 
blood samples by using Glyco-Tek Affinity Columns (Helena Biosciences Europe).  
SB-435495 and SB-568859 (GlaxoSmithKline) are potent and selective pharmacological inhibitors of Lp-PLA2 in 
a variety of species (36, 37). Pharmacokinetic analysis in a number of species suggested that the 
pharmacokinetic properties of SB-568859 were most applicable to studies in rabbits, whereas the properties of 
SB-435495 were best suited for studies in rat (38). SB435495 was formulated as a solution in 10% Captisol 
(Hovione) with 10 mM sodium acetate pH 4.5. For assessment of Lp-PLA2 inhibition by SB435495, blood 
samples were collected 24 h before treatment and 24 h after the final placebo/SB435495 drug dosing. Plasma 
was prepared by centrifugation at 13,000 × g and stored at −80 °C. SB435495 concentration was measured in 
25-µL plasma samples by using an analytical method based on protein precipitation, followed by HPLC/MS/MS 
analysis (detection range 1 ng/mL to 1,000 ng/mL). Lp-PLA2 activity was evaluated by determining the enzyme-
catalyzed release of [
3
H-] acetate from 1-O-Hexadecyl-2-O-[
3
H-]acetyl-sn-glycer-3-phophorylcholine. Reactions 
were extracted by using chloroform:methanol (1:1) and disintegrations per unit time (DPMs) in the aqueous 
layer determined by liquid scintillation counting. DPMs were converted to moles of product through 
normalization to a [
3
H-] PAF standard.  
Effects of Lp-PLA2 Inhibition of Diabetes-Induced Retinal Vasopermeability.  
BN rats were confirmed diabetic 10 d after STZ treatment and then randomly assigned into groups receiving 
either a once-daily i.p. injection of placebo (vehicle) or once-daily dosing of SB435495 (dosing at 10 mg/kg, 5 
mg/kg, 1 mg/kg, and 0.25 mg/kg). A separate group of nondiabetic, age-matched control BN rats received no 
treatment. After 28 d, animals were processed for analysis of retinal vascular leakage. In additional studies 
where the effect of combination of anti-VEGF and SB435495 therapies on diabetes-induced retinal 
vasopermeability was studied, anti-VEGF or control antibodies were introduced by intravitreal injections (1 µL 
volume) in both eyes, at day 26 after initial SB435495 administration.  
Retinal vasopermeability indicating breakdown of the BRB was assessed by using the Evans blue assay as 
described. Briefly, Evans blue dye (30 mg/mL in PBS) (Sigma Aldrich) was administered through the tail vein (45 
mg/kg) and allowed to circulate for 2 h before animals were terminally anesthetized with sodium 
pentobarbital. An intracardiac blood sample was collected before perfusion (20 mL/min for 5 min) through the 
left ventricle with 0.1 M citrate buffer pH 3.5. Retinas were isolated, freeze-dried, and extracted with 
formamide. Evans blue recovery in clarified samples was determined spectrophotometrically at 620 nm and 
740 nm and compared with terminal plasma samples collected from the same animals. Concentrations of 
Evans blue were derived from standard curves of the dye in formamide.  
Rat Retinal Immunostaining. 
Enucleated eyes were fixed in 4% paraformaldehyde. Eyes were bisected at the equator, cryoprotected by 
sequential overnight immersion in 10%, 20%, and 30% sucrose solution, and then embedded in optimal cutting 
temperature medium (CellPath Ltd). Serial 20-µm cryosections from the central and opposing peripheral 
retinal regions were collected on Superfrost plus slides. Frozen sections were rehydrated in 3% Triton X-100 in 
TBS for 30 min and blocked for 1 h in 1% donkey serum. Sections were incubated overnight at 4 °C with sheep 
anti-rat albumin antibody (1:500 dilution) (Bethyl Laboratories) and biotinylated Griffonia simplicifolia isolectin 
B4 (20 µg/mL) in blocking buffer (Sigma Aldrich). Sections were washed and stained with donkey anti-sheep 
Alexa Fluor 488 nm and streptavidin Alexa Fluor 568 nm. Sections were counterstained with DAPI, mounted 
with Vectashield (Vector Labs), and images captured with a confocal scanning laser microscope (Eclipse 
TE2000-U confocal microscope, Nikon). The area of albumin immunoreactivity in captured images was 
quantified by using Nikon NIS Elements image analysis software.  
Effects of Lp-PLA2 Inhibition on VEGF-Induced Retinal Vascular Hyperpermeability in Rabbits.  
Male HY79b pigmented rabbits (1,800–2,200 g, Hypharm) were treated with SB568859 (GlaxoSmithKline), a 
potent rabbit Lp-PLA2 inhibitor. SB568859 was administered orally, at 0 (vehicle alone), 3, 10, and 30 mg/kg, 
respectively, once on day 1, twice (8:00 AM and 4:00 PM) on days 2–5, and once on day 6. As positive control, 
2-mg triamcinolone acetonide (Kenacort) was injected into the vitreous on day 1. Retinal vascular leakage was 
induced through the intravitreal injection of 500 ng of recombinant VEGF (rhVEGF; R&D Systems) in the right 
eye of all animals on day 4. Blood samples were collected on day 4 and day 5 (before the scheduled SB568859 
dosing, equivalent to Ctrough), and on day 6 (∼2–3 h after the day 6 SB568859 dosing) for determination of 
SB568859 concentration and Lp-PLA2 enzyme activity. Fluorescein angiography and ocular fluorophotometry 
(FM) measurements were performed on day 6 to assess retinal vascular permeability. Forty-seven hours after 
rhVEGF injection, and 1 h (± 15 min) after the last SB568859 dosing, sodium fluorescein (10% in saline solution 
0.9%, 50 mg/kg) was injected into anesthetized rabbits via the marginal ear vein. After injection of the 
fluorescein tracer, three retinal angiograms (corresponding to the nasal, central and temporal retina) of the 
right eye were recorded by using a Heidelberg Retinal Angiograph (HRA, Heidelberg Engineering). All 
angiography images were assessed for retinal leakage by masked scoring by three individuals, using the 
following scoring system: 0, no leakage; 1, slight leakage; 2, moderate leakage; and 3, severe leakage. Leakage 
values were then averaged to assess changes in the BRB breakdown. In addition, 1 h following fluorescein 
injection, the presence of fluorophore was recorded in both eyes with a FM-2 Fluorotron Master ocular 
fluorophotometer (OcuMetrics). A series of 148 scans with a 0.25-mm step size were recorded from the 
cornea to the retina along the optical axis. The ratio of fluorescein content between the vitroretinal 
compartment of the right and left eyes was used to evaluate changes to the BRB.  
MVECs. 
Primary MVECs were isolated from rat brains or retinae and grown as described (21). Briefly, microvessels 
were isolated by enzymatic and mechanical disruption of tissue, purified on BSA and Percoll gradients, and 
further selected for by treatment with puromycin. Cells were seeded onto collagen IV/fibronectin and grown in 
EGM2-MV media (Lonza). A stable rat retinal MVEC line (PT2) was also used to provide the larger cell 
quantities necessary for biochemical analyses. These cells were derived from primary rat retinal MVECs by 
immortalization with a temperature-sensitive (tsa58) SV40 large T encoding retrovirus (39) and subsequent 
cloning. PT2s were grown on collagen IV/fibronectin in EGM2-MV media (Lonza).  
Recombinant Adenoviruses. 
Double-stranded oligonucleotides designed to encode small hairpin RNAs targeting either mouse and rat 
VEGFR1 (GATCCCGCCACATCGGCCATCATCTGAAGGAATTCGTTCAGATGATGGCCGATGTGGTTTTTA) or VEGFR2 
(GATCCCGCCATGTTCTTCTGGCTCCTTCGGAATTCGGAAGGAGCCAGAAGAACATGGTTTTTA) were subcloned into 
BamH1/Hind3 sites of pRNAT-H1.1/Shuttle (GenScript), where the transcript in question and that of GFP are 
under the control of the H1.1 and CMV promoter, respectively. Effectiveness of knockdown by these 
constructs was confirmed by transient transfection in the MVEC cell line. Subsequently, recombinant 
adenoviruses were prepared from these shuttle plasmids (VectorBiolabs). High-titer viral stocks were kept at 
−80 °C and used to infect primary MVECs at m.o.i. of 50–2,000.  
Vascular Permeability in Retinal and Brain MVECs. 
LPC (Cayman Chemical Company) was diluted into PBS, which was supplemented with 0.1% fatty-acid free 
BSA. SU1498 (Sigma) and PTK787/ZK222584 (PTK/ZK) were diluted from freshly made stocks (10 mM in 
DMSO). Flux measurements were performed as described by using 4-kDa FITC dextran (21). Briefly, cells were 
grown on transwells (6.5 mm, 0.4-µm pores; Corning) and dextran (1 mg/mL) added to the apical side. Flux 
was monitored in samples (30 μL) taken from the basal side at 20- to 30-min intervals. Baseline flux was 
recorded from untreated cells for 120 min, followed (optionally) by the baseline in the presence of small 
molecule inhibitors for at least another 60 min, and finally for an additional 120 min from when the vasoactive 
compounds were added. Fluorescence of samples was plotted against time and permeability changes were 
determined from linear slope changes average over 2 h before and after addition of the compound. LPC (10 
µg/mL) was added apically or basally for directionality experiments. Postconfluent primary MVECs were 
pretreated in the presence or absence of SU1498 (10 µM) or DMS1529 (10 µg/mL), and 4-kDa dextran flux was 
measured before and after the addition of 10 µg/mL LPC. In additional flux studies aflibercept (EYLEA; 25 
µg/mL) was added or not before measuring the flux induced by VEGF-A (50 ng/mL) or LPC (10 µg/mL).  
For TEER assays, cells were grown on 12-mm gold-coated ECIS grids (8W1E) and real-time impedance was 
acquired by using a 1600R device and firm software (all Applied Biophysics) to derive TEERs. At the start of 
experiments, TEER values were approximately 25,000 Ω and 15,000 Ω for brain and retinal MVECs, 
respectively.  
Vascular Permeability in Pial Microvessels in Vivo. 
In vivo permeability measurements in occluded pial microvessels were performed on Wistar rats (aged 25–30 
d) exactly as described by Hudson et al. (21). Briefly, the vasculature was filled with sulforhodamine B (580 Da, 
Sigma) before a microvessel on the pial surface was occluded by using a glass probe. Time-dependent loss of 
fluorescent signal from the occluded microvessels is solely due to permeability and was recorded by using 
video microscopy. Intensity mapping then allows calculation of vessel permeability and time-dependent 
changes using Ct = C0⋅e
-kt
; where k = 4P/d, and where Ct and C0 are the dye concentrations at time t and time 0, 
respectively; P is the permeability and d the diameter of the vessel. LPC was either delivered through the 
carotid artery (luminal application) or applied to a cranial window (abluminal) at various concentrations. 
Antagonist pretreatment was via the cranial window for 15 min before LPC application and permeability 
measurements.  
Immunoblot Analysis. 
For immunoblot analyses, treated PT2 cells were lysed in 50 mM Tris/Cl, pH 6.8, 2% SDS, 10% glycerol, 100 mM 
DTT, (50 μL/cm
2
 of cells), separated by SDS/PAGE and electrotransfered to nitrocellulose or PVDF. For each 
series of samples, two identically loaded gels/immunoblots were run for immunodecoration with phospho-
specific and total antibodies. All primary antibodies were from Cell Signaling Technology: anti-phospho-
VEGFR2 (Y1175), anti-VEGFR2 (55B11), anti-phospho-p38 (T180/Y182) (9211), and anti-p38 (9212).  
 
 
Fig. S1. Characterization of BN rats following induction of diabetes and 28-d dosing with the selective Lp-PLA2 
inhibitor SB435495. (A) Mean change in rat body weight over the course of the experiment. Diabetic (DB) 
animals gained significantly less body weight over the course of the experiment compared with the 
nondiabetic (NDB) control group of animals. One-way ANOVA (***P < 0.001). (B) Associated HbA1c levels in BN 
rats, 28 d after initial SB435495 dosing. Placebo-treated and SB435495-treated DB rats had significantly 
elevated glycated hemoglobin levels compared with NDB control animals, and drug-treatment had no effect 
on overall HbA1c levels. One-way ANOVA (***P < 0.001).  
  
 
Fig. S2. Histological assessment of diabetes-induced retinal vasopermeability in BN rats. Representative rat 
retinal sections stained with isolectin B4 to assess retinal vasculature (red), and anti-rat albumin antibody 
(green) to assess albumin extravsation from the retinal vessels. Significant vascular leakage of albumin was 
observed in the diabetic (DB) placebo-treated animals compared with nondiabetic (NDB) control animals. This 
leakage, indicated by the arrows on the micrographs, primarily emanated from dilated retinal vessels (marked 
with an asterisk) and was focal in nature. Low-dose (1 mg/kg) SB435495 treatment resulted in the 
reestablishment of areas of retinal vasopermeability, which also arose from dilated vessels. (Objective 
magnification: 40×.) (Scale bars: 50 µm.)  
  
 
Fig. S3. Efficacy of SB435495 administered curatively to prevent diabetes-induced albumin extravasation. BN 
rats were rendered diabetic by a single i.p. injection of STZ and maintained hyperglycemic for 28 d before 
receiving a single daily i.p. injection of placebo or 10 mg/kg SB435495 for a further 28 d. At the end of the 
experimental period, retinal vascular permeability was assessed by confocal microscopy of rat retinal sections 
for extravasted albumin. Significant vascular leak was observed in the diabetic (DB) placebo-treated animals 
compared with the nondiabetic (NDB) control animals. Albumin leakage was markedly less pronounced in the 
10 mg/kg SB435495-treated rats. n = 3 animals per treatment group. (Objective magnification: 40×.) (Scale 
bars: 50 µm.)  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S4. Effect of Lp-PLA2 inhibition in VEGF-induced retinal leak in HY79b-pigmented rabbits. HY79b-pigmented 
male rabbits were treated with SB568859 at 0 (vehicle alone) (n = 6), 3 (n = 6), 10 (n = 8), and 30 mg/kg, 
respectively (n = 8), once on day 1, twice (8:00 AM and 4:00 PM) on days 2–5, and once on day 6. On day 4, 
500 ng of rhVEGF was injected intravitreally into the right eye. Retinal vascular leak in the rabbit retina was 
determined by using fundus fluorescein angiography at day 6. (A) Pharmokinetic profile of SB568859 in rabbit 
plasma at days 4, 5, and 6 following dosing. (B) Mean retinal vascular leak in the rabbit retina using flurotron 
values. Error bars represent 95% confidence limits. One-way ANOVA (*P < 0.05). (C) Retinal vascular leak in the 
rabbit retina following SB568859 treatment as assessed by morphometric scoring of fluorescein angiography 
images. Bars represent medians with the 25 and 75 percentiles shown by whiskers. One-way ANOVA, Tukey 
post test (*P < 0.05). LPC-induced permeability and VEGF receptor signaling. (D) Representative rabbit retinal 
fluorescein angiograms that were assessed for inhibition of VEGF-induced retinal leakage.  
 
  
 
 
Fig. S5. Characterization of retinal MVECs (PT2). Freshly isolated primary retinal MVECs were immortalized by 
using a retrovirus coding for temperature-sensitive large T. Immortalized cells were cloned, and one clone 
termed PT2 was further characterized. PT2 have been maintained for up to 20 passages. TEER was 33.6 (± 7) 
Ω.cm
2
 (n = 12) compared with approximately 150 Ω.cm
2
 usually achieved in primary retinal MVECs. The 
permeability coefficient for 4-kDa FITC-dextran flux across PT2 was 21.5 ± 10
−6
 cm/s, n = 6) (in parallel 
experiments, primary brain MVECs gave 3.9 ± 0.6 10
−6
 cm/s, n = 5). (A) Phase contrast image of confluent 
primary rat retinal and PT2 MVECs. (B) PT2 were stained for fixed and stained for endothelial cell markers: VE-
Cadherin, PECAM-1, and von Willebrand Factor (vWF); blood–brain barrier markers: transferrin receptor and 
p-glycoprotein; and also junctional markers: ZO-1, occludin, claudin-5, α-catenin, β-catenin, γ-catenin, and 
p120. (C) PT2 were grown on permeable transwell supports, and 40-kDa dextran flux was measured in the 
presence or absence of VEGF (50 ng/mL). (Scale bars: A, 50 μm; B, 10 μm.)  
  
Group (n = 6–8)  
Day 4 Day 5 Day 6 
PK, ng/mL
*
 
Lp-PLA2 
activity
†
 
PK, ng/mL
*
 
Lp-PLA2 
activity
†
 
PK, ng/mL
*
 
Lp-PLA2 
activity
†
 
Vehicle PO BID
‡
 BLQ 20.78 ± 0.57 BLQ 18.90 ± 0.43 BLQ 20.40 ± 0.72 
SB568859 3 mg/kg PO 
BID 
31.21 ± 
3.84 
13.95 ± 0.95 
27.85 ± 
1.71 
13.28 ± 0.46 
34.87 ± 
3.62 
12.24 ± 1.33
‡
 
SB568859 10 mg/kg PO 
BID 
48.93 ± 
1.88 
6.01 ± 0.62 
47.76 ± 
3.32 
5.61 ± 0.39
‡
 
47.55 ± 
2.25 
3.71 ± 0.41 
SB568859 30 mg/kg PO 
BID 
69.79 ± 
7.27 
3.01 ± 0.36
‡
 
59.60 ± 
5.72 
2.59 ± 0.27
‡
 
68.10 ± 
5.94 
1.58 ± 0.19 
Kenacort IVT — — — — BLQ 21.65 ± 0.72 
 
Table S1. Rabbit plasma exposure of SB568859 and plasma Lp-PLA2 activity at days 4, 5, and 6 and following 
administration of 3–30 mg⋅kg
−1
⋅d
−1
 SB568859 by oral gavage  
Male HY79b-pigmented rabbits were treated with SB568859 administered by mouth, at 0 (vehicle alone, n = 
6), 3 (n = 6), 10 (n = 8), and 30 mg/kg, respectively, (n = 8) at each dose, once on day 1, twice (8 AM and 4 PM) 
on days 2–5, and once on day 6. Blood samples were collected on day 4 and day 5 (before the scheduled 
SB568859 dosing, equivalent to Ctrough), and on day 6 (∼2–3 h after the day 6 SB568859 dosing) for 
determination of SB568859 concentration and Lp-PLA2 enzyme activity. Plasma was prepared by centrifugation 
at 13,000 x g and stored at −80 °C. SB568859 concentration was measured following protein precipitation by 
HPLC/MS/MS analysis. Lp-PLA2 activity was evaluated by determining the enzyme-catalyzed release of [
3
H-] 
acetate from 1-O-hexadecyl-2-O-[
3
H-]acetyl-sn-glycer-3-phophorylcholine. BLQ, below level of quantitation; PO 
BID, by mouth, twice a day. * ng SB568859/ml rabbit plasma, mean ± standard deviation of the mean. † Lp-
PLA2 enzyme rate (nmol/min/mL), mean ± standard deviation of the mean. ‡ Indicates n = 7.  
 
